New Stock News | Lianchi Hospital is planning a Hong Kong IPO. The China Securities Regulatory Commission has requested additional information on whether the company is involved in providing personal user information to third parties.

The China Securities Regulatory Commission issued the "Supplementary Materials Requirements for Overseas Issuance and Listing Record (May 11, 2026 - May 15, 2026)." The International Department of the China Securities Regulatory Commission has issued supplementary material requirements to 14 companies. Among them, Lianchi Hospital is required to provide additional information on the products such as websites, apps, mini programs developed and operated by the company, the scale of user information collected and stored, data collection and usage, and whether it involves providing personal user information to third parties. According to the Hong Kong Stock Exchange on January 13, Lianchi Hospital Group Limited has submitted a listing application to the main board of the Hong Kong Stock Exchange, with China Galaxy International as its exclusive sponsor. The China Securities Regulatory Commission has requested Lianchi Hospital to provide additional information on the following matters, and to have a lawyer verify and provide clear legal opinions: 1. Please provide additional information on the products such as websites, apps, mini programs developed and operated by your company, the scale of user information collected and stored, data collection and usage, whether it involves providing personal user information to third parties, and the arrangements or measures for personal information protection and data security before and after listing. 2. Please provide additional information on the specific use of funds raised by your company, including the planned investment proportions and amounts. According to the prospectus, Lianchi Hospital is a Chinese specialty boutique medical group. As of September 30, 2025, Lianchi Hospital operated 5 hospitals and a nursing home under a group management structure. The company has always adhered to the core value of "patient-centered" and implemented a "human-centered medical" management model, forming a well-known medical brand "Lianchi Medical" with characteristic medical service models such as painless management, enhanced recovery after surgery (ERAS), integrated medical and nursing care, and caregiver-free nursing. According to Frost & Sullivan data, Lianchi Hospital has become one of the most influential medical groups in China. According to Frost & Sullivan data, based on the number of knee surgeries in private hospitals in 2024, the company's Zibo Lianchi Orthopedic Hospital ranked first in Shandong province and third nationwide. According to Frost & Sullivan data, based on revenue in 2024, the company's Chongqing Great Wall Orthopedic Hospital ranked first among private orthopedic specialty hospitals in southwest China.